• 1
    Jemal A, Thun MJ, Ries LA, et al. Annual report to the nation on the status of cancer, 1975-2005, featuring trends in lung cancer, tobacco use, and tobacco control. J Natl Cancer Inst. 2008; 100: 1672-1694.
  • 2
    National Cancer Institute. Surveillance, Epidemiology, and End Results. Available at: Accessed November 15, 2009.
  • 3
    Burris HA III. Recent updates on the role of chemotherapy in pancreatic cancer. Semin Oncol. 2005; 32: S1-3.
  • 4
    Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2008. CA Cancer J Clin. 2008; 58: 71-96.
  • 5
    Ghaneh P, Costello E, Neoptolemos JP. Biology and management of pancreatic cancer. Gut. 2007; 56: 1134-1152.
  • 6
    Burris HAIII, Moore MJ, Andersen J, et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol. 1997; 15: 2403-2413.
  • 7
    Rothenberg ML, Moore MJ, Cripps MC, et al. A phase II trial of gemcitabine in patients with 5-FU-refractory pancreas cancer. Ann Oncol. 1996; 7: 347-353.
  • 8
    Moore MJ, Goldstein D, Hamm J, et al. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol. 2007; 25: 1960-1966.
  • 9
    Berlin JD, Catalano P, Thomas JP, Kugler JW, Haller DG, Benson AB III. Phase III study of gemcitabine in combination with fluorouracil versus gemcitabine alone in patients with advanced pancreatic carcinoma: Eastern Cooperative Oncology Group Trial E2297. J Clin Oncol. 2002; 20: 3270-3275.
  • 10
    Heinemann V, Quietzsch D, Gieseler F, et al. Randomized phase III trial of gemcitabine plus cisplatin compared with gemcitabine alone in advanced pancreatic cancer. J Clin Oncol. 2006; 24: 3946-3952.
  • 11
    Colucci G, Giuliani F, Gebbia V, et al. Gemcitabine alone or with cisplatin for the treatment of patients with locally advanced and/or metastatic pancreatic carcinoma: a prospective, randomized phase III study of the Gruppo Oncologia dell'Italia Meridionale. Cancer. 2002; 94: 902-910.
  • 12
    Schneider BP, Ganjoo KN, Seitz DE, et al. Phase II study of gemcitabine plus docetaxel in advanced pancreatic cancer: a Hoosier Oncology Group study. Oncology. 2003; 65: 218-223.
  • 13
    Stathopoulos GP, Mavroudis D, Tsavaris N, et al. Treatment of pancreatic cancer with a combination of docetaxel, gemcitabine and granulocyte colony-stimulating factor: a phase II study of the Greek Cooperative Group for Pancreatic Cancer. Ann Oncol. 2001; 12: 101-103.
  • 14
    Jacobs AD, Otero H, Picozzi VJJr, Aboulafia DM. Gemcitabine combined with docetaxel for the treatment of unresectable pancreatic carcinoma. Cancer Invest. 2004; 22: 505-514.
  • 15
    Lutz MP, Van Cutsem E, Wagener T, et al. Docetaxel plus gemcitabine or docetaxel plus cisplatin in advanced pancreatic carcinoma: randomized phase II study 40984 of the European Organisation for Research and Treatment of Cancer Gastrointestinal Group. J Clin Oncol. 2005; 23: 9250-9256.
  • 16
    Louvet C, Labianca R, Hammel P, et al. Gemcitabine in combination with oxaliplatin compared with gemcitabine alone in locally advanced or metastatic pancreatic cancer: results of a GERCOR and GISCAD phase III trial. J Clin Oncol. 2005; 23: 3509-3516.
  • 17
    Poplin E, Feng Y, Berlin J, et al. Phase III, randomized study of gemcitabine and oxaliplatin versus gemcitabine (fixed-dose rate infusion) compared with gemcitabine (30-minute infusion) in patients with pancreatic carcinoma E6201: a trial of the Eastern Cooperative Oncology Group. J Clin Oncol. 2009; 27: 3778-3785.
  • 18
    Herrmann R, Bodoky G, Ruhstaller T, et al. Gemcitabine plus capecitabine compared with gemcitabine alone in advanced pancreatic cancer: a randomized, multicenter, phase III trial of the Swiss Group for Clinical Cancer Research and the Central European Cooperative Oncology Group. J Clin Oncol. 2007; 25: 2212-2217.
  • 19
    Stathopoulos GP, Syrigos K, Aravantinos G, et al. A multicenter phase III trial comparing irinotecan-gemcitabine (IG) with gemcitabine (G) monotherapy as first-line treatment in patients with locally advanced or metastatic pancreatic cancer. Br J Cancer. 2006; 95: 587-592.
  • 20
    Reni M, Passoni P, Panucci MG, et al. Definitive results of a phase II trial of cisplatin, epirubicin, continuous-infusion fluorouracil, and gemcitabine in stage IV pancreatic adenocarcinoma. J Clin Oncol. 2001; 19: 2679-2686.
  • 21
    Sultana A, Ghaneh P, Cunningham D, Starling N, Neoptolemos JP, Smith CT. Gemcitabine based combination chemotherapy in advanced pancreatic cancer-indirect comparison. BMC Cancer. 2008; 8: 192.
  • 22
    Sultana A, Smith CT, Cunningham D, Starling N, Neoptolemos JP, Ghaneh P. Meta-analyses of chemotherapy for locally advanced and metastatic pancreatic cancer. J Clin Oncol. 2007; 25: 2607-2615.
  • 23
    Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst. 2000; 92: 205-216.
  • 24
    Ratain MJ, Eisen T, Stadler WM, et al. Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma. J Clin Oncol. 2006; 24: 2505-2512.
  • 25
    National Cancer Institute. Common Terminology Criteria for Adverse Events v3.0. Available at: Accessed on February 4, 2010.
  • 26
    National Institutes of Health. Available at: Accessed October 27, 2009.
  • 27
    Von Hoff DD, Ramanathan R, Borad M, et al. SPARC correlation with response to gemcitabine (G) plus nab-paclitaxel (nab-P) in patients with advanced metastatic pancreatic cancer: a phase I/II study [abstract]. J Clin Oncol. 2009; 27 ( suppl). Abstract 4525.
  • 28
    Smith LS, Drengler RL, Wood TE, et al. SPARC and CA19-9 as biomarkers in patients with advanced pancreatic cancer treated with nab paclitaxel plus gemcitabine [abstract]. J Clin Oncol. 2008; 26( 15 suppl). Abstract 15592.
  • 29
    Scholl C, Frohling S, Dunn IF, et al. Synthetic lethal interaction between oncogenic KRAS dependency and STK33 suppression in human cancer cells. Cell. 2009; 137: 821-834.
  • 30
    Ciuleanu TE, Pavlovsky AV, Bodoky G, et al. A randomised Phase III trial of glufosfamide compared with best supportive care in metastatic pancreatic adenocarcinoma previously treated with gemcitabine. Eur J Cancer. 2009; 45: 1589-1596.
  • 31
    National Cancer Institute. Pancreatic Cancer Treatment: Treatment Option Overview. Available at: Accessed on October 27, 2009.
  • 32
    Maisey NR, Norman AR, Hill A, Massey A, Oates J, Cunningham D. CA19-9 as a prognostic factor in inoperable pancreatic cancer: the implication for clinical trials. Br J Cancer. 2005; 93: 740-743.
  • 33
    Wheler J, Tsimberidou AM, Hong D, et al. Survival of patients in a Phase 1 Clinic: the MD. Anderson Cancer Center experience. Cancer. 2009; 115: 1091-1099.
  • 34
    Tsimberidou AM, Vaklavas C, Wen S, et al. Phase I clinical trials in 56 patients with thyroid cancer: the M. D. Anderson Cancer Center experience. J Clin Endocrinol Metab. 2009; 94: 4423-4432.
  • 35
    Dhillon N, Aggarwal BB, Newman RA, et al. Phase II trial of curcumin in patients with advanced pancreatic cancer. Clin Cancer Res. 2008; 14: 4491-4499.
  • 36
    Naing A, Reuben JM, Verschraegen CF, et al. Phase I dose-escalation study of sodium stibogluconate, a protein tyrosine phosphatase inhibitor, combined with interferon-alfa for patients with solid tumors [abstract]. J Clin Oncol. 2008; 26 ( suppl). Abstract 3011.
  • 37
    Adjei AA, Cohen RB, Kurzrock R, et al. Results of a phase I trial of KX2-391, a novel non-ATP competitive substrate-pocket directed SRC inhibitor, in patients with advanced malignancies [abstract]. J Clin Oncol. 2009; 27( 15 suppl). Abstract 3511.
  • 38
    National Institutes of Health. An open label phase I study to evaluate the effects of patupilone on the pharmacokinetics of midazolam and omeprazole in patients with advanced malignancies (NCT00420615). Available at: Accessed October 12, 2009.
  • 39
    Falchook GS, Moulder S, Wheler JJ, et al. Combination trastuzumab, lapatinib, and bevacizumab in HER2+ breast cancer and other malignancies. 32nd Annual San Antonio Breast Cancer Symposium, San Antonio, Texas, December 9–13, 2009.
  • 40
    Chintala L, Kurzrock R, Fu S, et al. Phase I study of tipifarnib and sorafenib in patients with biopsiable advanced cancer (NCI protocol 7156). J Clin Oncol. 2008; 26( 15 suppl): 3593.